Opthea (OPT) Stock Price, News & Analysis

Company Overview

Opthea Limited (NASDAQ:OPT) is a clinical-stage biopharmaceutical company focused on developing novel therapies for retinal vascular diseases. The company’s lead product candidate, OPT-302, is designed to inhibit vascular endothelial growth factors C and D (VEGF-C/D) and is being evaluated as a potential treatment for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Opthea’s research strategy aims to complement existing anti-VEGF-A therapies by providing a broader blockade of the VEGF family to address residual vision loss in patients receiving standard care.

OPT-302 has advanced through multiple clinical trials, including a Phase 2b study in wet AMD patients and a Phase 1/2 trial in DME patients. Data from these trials have demonstrated promising safety and efficacy signals, including improvements in visual acuity and reductions in retinal fluid. Opthea collaborates with global contract research organizations and ophthalmology centers to support its clinical development program, with ongoing studies designed to establish optimal dosing regimens and confirm long-term benefits.

Founded in 2009 based on research conducted at the Walter and Eliza Hall Institute in Melbourne, Opthea is headquartered in Melbourne, Australia, with strategic operations in North America. The company’s management team combines expertise in ophthalmology, clinical development, regulatory affairs and commercialization to advance its pipeline toward potential regulatory approvals. Opthea is committed to addressing unmet medical needs in retinal diseases and to creating value for patients, healthcare providers and investors through its innovative therapeutic approach.

Key Stats

• Today's Range: $3.25 to $3.48
• 50-Day Range: $3.41 to $3.41
• 52-Week Range: $1.79 to $6.30
• Volume: 3,000 shs
• Average Volume: N/A
• Market Capitalization: $583.11 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $1.33
• Consensus Rating: Hold

Opthea Stock Analysis - MarketRank™

Opthea scored higher than 10% of companies evaluated by MarketBeat, and ranked 932nd out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.1 / 5
• Analyst Rating: Hold

Consensus Rating

Opthea has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on no buy ratings, 4 hold ratings, and 1 sell rating.

Downside Risk

Opthea has a consensus price target of $1.33, representing about 60.9% downside from its current price of $3.41.

Amount of Analyst Coverage

Opthea has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Opthea are expected to grow in the coming year, from ($1.39) to ($0.67) per share.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for OPT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Opthea does not currently pay a dividend.

Dividend Growth

Opthea does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for OPT.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Opthea has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Opthea this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for OPT on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Opthea insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.20% of the stock of Opthea is held by insiders.

Percentage Held by Institutions

55.95% of the stock of Opthea is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

OPT Stock Analysis - Frequently Asked Questions

How have OPT shares performed this year?

Opthea's stock was trading at $3.93 on January 1st, 2025. Since then, OPT stock has decreased by 13.2% and is now trading at $3.41.

When did Opthea IPO?

Opthea (OPT) raised $161 million in an IPO on Friday, October 16th 2020. The company issued 9,300,000 shares at $17.26 per share. Citigroup and SVB Leerink acted as the underwriters for the IPO and Oppenheimer & Co. and Truist Securities were co-managers.

How do I buy shares of Opthea?

Shares of OPT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Opthea own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Opthea investors own include PayPal (PYPL), Sunrun (RUN), Avino Silver & Gold Mines (ASM), QUALCOMM (QCOM), Ross Stores (ROST), Zendesk (ZEN) and Adobe (ADBE).

Company Calendar

• Today: 9/12/2025
• Next Earnings (Estimated): 9/12/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OPT
• CIK: 1815620
• Web: www.opthea.com
• Phone: 61-3-9826-0399
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Opthea: $1.33
• High Price Target: $2.00
• Low Price Target: $1.00
• Potential Upside/Downside: -60.9%
• Consensus Rating: Hold
• Rating Score (0-4): 2.17
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $87.67 thousand
• Price / Sales: 5,986.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.31) per share
• Price / Book: -2.60

Miscellaneous

• Outstanding Shares: 153,911,000
• Free Float: 165,525,000
• Market Cap: $524.84 million
• Optionable: Not Optionable
• Beta: 1.12